#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Gastrointestinal stromal tumour Inflammatory myofibroblastic tumour Round cell liposarcoma Prolymphocytic leukaemia Henoch-Schonlein purpura nephritis Stevens-Johnson syndrome Congenital aplastic anaemia Corneal neovascularisation Thalassaemia beta Autoimmune hepatitis Oropharyngeal cancer recurrent Ovarian cancer stage IV Mitochondrial encephalomyopathy Biotinidase deficiency Leiomyosarcoma More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis III Familial haemophagocytic lymphohistiocytosis – Treatment Mucous membrane pemphigoid – Diagnostics Idiopathic inflammatory myopathy – Trials in Disease Lennox-Gastaut syndrome – Life with Disease Mantle cell lymphoma stage IV – Life with Disease Hereditary neuropathic amyloidosis – Life with Disease Glomerulonephritis rapidly progressive – Basic Information Osteosarcoma metastatic – Diagnostics Piriformis syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Granisetron Triptorelin Acetate Batoprotafib Pemetrexed Ecoo1A GOVORESTAT Betula Pendula Pollen Extract Cetuximab Tafamidis Lolium Perenne Pollen Extract AMO959 Tepotinib Thiopental Sodium Sodium Iotalamate (125I) Glucagon AMMONIUM (15N) CHLORIDE Tumor Necrosis Factor-Alpha Efgartigimod Alfa Ima203Cd8 Rapcabtagene Autoleucel More therapies…

    Learn about Your Condition

    Colon cancer Hereditary ataxia Acute leukaemia Ebola disease Seasonal allergy Metabolic syndrome Depression Endolymphatic hydrops Familial mediterranean fever Polyneuropathy Choroidal neovascularisation Diabetic ketoacidosis Univentricular heart Meniscus operation Hypoparathyroidism More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2ai Bsqkvwczn Dl Smjlbj Mrmamhygwbd Br 1krk Mhtuacfecu 1apfdq Fojljw

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Glatiramer Acetate
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    Belgium Denmark France Germany Italy The Netherlands +1

  • First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    Investigated Drugs:
    • (2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
    Austria Belgium Czechia Denmark France Germany +6

  • Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Fulvestrant
    • Ly3484356
    Belgium France Hungary Ireland Poland Portugal +2

  • Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Epirubicin Hydrochloride
    • Carboplatin
    • Cyclophosphamide Monohydrate
    France

  • Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Camizestrant
    France

  • Durvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Durvalumab
    France

  • Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Pneumonia
    • Influenza
    Investigated Drugs:
    • Dexamethasone Phosphate
    • Sodium Chloride
    France

  • Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Capecitabine
    • Temozolomide
    France

  • Study of denikitug alone or with drug combination in adults with HER2‑negative metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Nivolumab
    • Paclitaxel Albumin-Bound
    • Ramucirumab
    France Spain

  • Study of denikitug alone or in drug combination in adults with advanced microsatellite stable colorectal cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Bevacizumab
    • Nivolumab
    • Tipiracil Hydrochloride
    France Italy Spain
Previous Page
1 … 17 18 19 20 21 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!